Steven Devine

Steven Devine

UNVERIFIED PROFILE

Are you Steven Devine?   Register this Author

Register author
Steven Devine

Steven Devine

Publications by authors named "Steven Devine"

Are you Steven Devine?   Register this Author

100Publications

4904Reads

42Profile Views

Comparison of Two Doses of Antithymocyte Globulin in Reduced-Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation.

Biol Blood Marrow Transplant 2019 Oct 20;25(10):1993-2001. Epub 2019 Jun 20.

Division of Hematology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2019.06.014DOI Listing
October 2019

Tocilizumab as first-line therapy for steroid-refractory acute graft-versus-host-disease: analysis of a single-center experience.

Leuk Lymphoma 2019 Sep 15;60(9):2223-2229. Epub 2019 Feb 15.

Department of Pharmacy, The James Cancer Hospital, The Ohio State University Comprehensive Cancer Center , Columbus , Ohio , 43210 , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428194.2019.1573996DOI Listing
September 2019

Flt3L Treatment of Bone Marrow Donors Increases Graft Plasmacytoid Dendritic Cell Content and Improves Allogeneic Transplantation Outcomes.

Biol Blood Marrow Transplant 2019 Jun 29;25(6):1075-1084. Epub 2018 Nov 29.

Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, Georgia. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S10838791183077
Publisher Site
http://dx.doi.org/10.1016/j.bbmt.2018.11.029DOI Listing
June 2019

Defining Competency to Empower Blood and Marrow Transplant and Cellular Immunotherapy Quality Management Professionals in Healthcare.

Biol Blood Marrow Transplant 2019 01 21;25(1):179-182. Epub 2018 Aug 21.

Blood and Marrow Transplant and Cellular Immunotherapy Program, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S10838791183048
Publisher Site
http://dx.doi.org/10.1016/j.bbmt.2018.08.017DOI Listing
January 2019

A challenge to discriminating psychosocial eligibility criteria: exploring the ethical justification for excluding patients with psychosocial risk factors from hematopoietic cell transplantation.

Bone Marrow Transplant 2018 11 6;53(11):1474-1477. Epub 2018 Jun 6.

Center for Bioethics and Medical Humanities, and Department of Palliative Care, The Ohio State University, Columbus, Ohio, USA.

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41409-018-0213-6
Publisher Site
http://dx.doi.org/10.1038/s41409-018-0213-6DOI Listing
November 2018

A retrospective review of fall risk factors in the bone marrow transplant inpatient service.

J Oncol Pharm Pract 2018 Jun 16;24(4):272-280. Epub 2017 Mar 16.

4 The James Cancer Hospital and Solove Research Institute, The Ohio State University Wexner Medical Center, Columbus, OH, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1078155217697485DOI Listing
June 2018

G-CSF improves safety when you start the day after autologous transplant in multiple myeloma.

Leuk Lymphoma 2017 12 16;58(12):2947-2951. Epub 2017 May 16.

a Division of Hematology, Department of Internal Medicine, College of Medicine, t he Ohio State University , Columbus , OH , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428194.2017.1318436DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6607907PMC
December 2017

The who, how and why: Allogeneic transplant for acute myeloid leukemia in patients older than 60years.

Blood Rev 2017 11 15;31(6):362-369. Epub 2017 Jul 15.

Division of Hematology, Ohio State University, Columbus, OH, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.blre.2017.07.002DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6205157PMC
November 2017

Time-to-Event Ratio to Predict Outcome in Patients with Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation?

Biol Blood Marrow Transplant 2017 10 5;23(10):1804-1808. Epub 2017 Jul 5.

Division of Hematology-Oncology and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, Minnesota.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2017.06.016DOI Listing
October 2017

Haploidentical Hematopoietic Cell Transplantation Using Post-Transplantation Cyclophosphamide: Does Graft Source Matter?

Authors:
Steven M Devine

J Clin Oncol 2017 09 10;35(26):2984-2986. Epub 2017 Jul 10.

Steven M. Devine, The Ohio State University Comprehensive Cancer Center, Columbus, OH.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2017.73.7775
Publisher Site
http://dx.doi.org/10.1200/JCO.2017.73.7775DOI Listing
September 2017

Clinical Cancer Advances 2017: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology.

J Clin Oncol 2017 04 1;35(12):1341-1367. Epub 2017 Feb 1.

Harold J. Burstein and Steven G. DuBois, Dana-Farber Cancer Institute; Rebecca A. Miksad and Nadine Tung, Beth Israel Deaconess Medical Center; Lori J. Wirth and Don S. Dizon, Massachusetts General Hospital, Boston, MA; Lada Krilov and Richard L. Schilsky, American Society of Clinical Oncology, Alexandria; Jeanny B. Aragon-Ching, Inova Schar Cancer Institute, Fairfax, VA; E. Gabriela Chiorean, University of Washington, Seattle, WA; Warren Allen Chow, City of Hope, Duarte, CA; John Frederick De Groot and John Heymach, University of Texas MD Anderson Cancer Center, Houston, TX; Steven Michael Devine, Ohio State University, Columbus; Nathan A. Pennell, Cleveland Clinic, Cleveland, OH; Wafik S. El-Deiry, Fox Chase Cancer Center; Joshua Adam Jones, University of Pennsylvania Health Systems; Lynn Mara Schuchter, University of Pennsylvania, Philadelphia, PA; Andrew S. Epstein, Memorial Sloan Kettering Cancer Center, New York, NY; Deborah K. Mayer, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill; Karen Marie Winkfield, Wake Forest Baptist Medical Center, Winston-Salem, NC; Michael S. Sabel, University of Michigan, Ann Arbor, MI; and Nancy N. Baxter, St Michael's Hospital, University of Toronto, Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.71.5292DOI Listing
April 2017

Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes.

J Clin Oncol 2017 Apr 13;35(11):1154-1161. Epub 2017 Feb 13.

Bart L. Scott and H. Joachim Deeg, Fred Hutchinson Cancer Research Center, Seattle, WA; Marcelo C. Pasquini, Brent R. Logan, Mehdi Hamadani, and Mary M. Horowitz, Medical College of Wisconsin, Milwaukee, WI; Juan Wu and Adam M. Mendizabal, Emmes Corporation, Rockville, MD; Steven M. Devine, Ohio State University Comprehensive Cancer Center, Columbus, OH; David L. Porter, University of Pennsylvania, Philadelphia, PA; Richard T. Maziarz, Oregon Health and Science University, Portland, OR; Erica D. Warlick, University of Minnesota, Minneapolis; Jennifer Le-Rademacher, Mayo Clinic, Rochester, MN; Hugo F. Fernandez, Moffitt Cancer Center, Tampa, FL; Edwin P. Alyea, Dana Farber Cancer Institute, Boston, MA; Asad Bashey, Northside Hospital Cancer Institute, Atlanta, GA; Sergio Giralt, Memorial Sloan Kettering Cancer Center, New York, NY; Nancy L. Geller and Eric Leifer, National Heart, Lung, and Blood Institute, Bethesda, MD; and Mitchell E. Horwitz, Duke University, Durham, NC.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.70.7091DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5455603PMC
April 2017

High-dose immunosuppressive therapy and autologous HCT for relapsing-remitting MS.

Neurology 2017 Feb 1;88(9):842-852. Epub 2017 Feb 1.

From the Colorado Blood Cancer Institute (R.A.N.), Denver; Baylor College of Medicine (G.J.H.), Houston, TX; Ohio State University (M.K.R., S.M.D.), Columbus; MD Anderson Cancer Research Center (U.P.), Houston, TX; Rho, Inc. (K.C.S.), Chapel Hill, NC; National Institute of Allergy and Infectious Diseases (L.M.G.), National Institutes of Health, Bethesda, MD; Division of Brain Sciences (P.A.M.), Imperial College London, UK; City of Hope National Medical Center (H.O.), Duarte, CA; Immune Tolerance Network (P.H.S.), University of California San Francisco; University of Texas Southwestern (O.S.), Dallas; NeuroRx (D.L.A.), McGill University, Montreal, Canada; Fred Hutchinson Cancer Research Center (G.E.G.), University of Washington (M.H.W., A.W., G.H.K.); and Swedish Hospital Medical Center (J.D.B.), Seattle, WA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1212/WNL.0000000000003660DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5331868PMC
February 2017

Practice Patterns and Preferences Among Hematopoietic Cell Transplantation Clinicians.

Biol Blood Marrow Transplant 2016 11 29;22(11):2092-2099. Epub 2016 Jul 29.

Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5067220PMC
http://dx.doi.org/10.1016/j.bbmt.2016.07.014DOI Listing
November 2016

Tocilizumab for steroid refractory acute graft-versus-host disease.

Leuk Lymphoma 2016 3;57(1):81-5. Epub 2015 Jul 3.

b Division of Hematology, Department of Internal Medicine , James Cancer Hospital, The Ohio State University Comprehensive Cancer Center , Columbus , Ohio , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3109/10428194.2015.1045896DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4698359PMC
October 2016

How do stem cells mobilize? Bridging the GAP.

Authors:
Steven M Devine

Blood 2016 09;128(11):1445-6

THE OHIO STATE UNIVERSITY COMPREHENSIVE CANCER CENTER.

View Article

Download full-text PDF

Source
http://www.bloodjournal.org/cgi/doi/10.1182/blood-2016-07-72
Publisher Site
http://dx.doi.org/10.1182/blood-2016-07-726414DOI Listing
September 2016

Allogeneic hematopoietic cell transplantation in systemic mastocytosis: is there a high risk for veno-occlusive disease?

Eur J Haematol 2016 Jun 22;96(6):655-7. Epub 2016 Jan 22.

Division of Hematology-Oncology and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, MN, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ejh.12720DOI Listing
June 2016

Phase II Study of Allogeneic Transplantation for Older Patients With Acute Myeloid Leukemia in First Complete Remission Using a Reduced-Intensity Conditioning Regimen: Results From Cancer and Leukemia Group B 100103 (Alliance for Clinical Trials in Oncology)/Blood and Marrow Transplant Clinical Trial Network 0502.

J Clin Oncol 2015 Dec 2;33(35):4167-75. Epub 2015 Nov 2.

Steven M. Devine and William Blum, Ohio State University, Columbus, OH; Kouros Owzar, Flora Mulkey, Vera Hars, and Alexander B. Sibley, Alliance Statistics and Data Center, Duke University, Durham; Thomas C. Shea, University of North Carolina, Chapel Hill, NC; Richard M. Stone, Robert J. Soiffer, and Edwin P. Alyea, Dana-Farber Cancer Institute; Yi-Bin Chen, Massachusetts General Hospital, Boston, MA; Jack W. Hsu, University of Florida, Gainesville, FL; Richard E. Champlin, MD Anderson Cancer Research Center, Houston, TX; Ravi Vij, Washington University, St. Louis, MO; James Slack, Mayo Clinic, Scottsdale, AZ; Richard A. Larson, University of Chicago, Chicago, IL; Sergio Giralt, Memorial Sloan Kettering Cancer Center, New York, NY; Shelly Carter, The EMMES Corporation, Bethesda, MD; Mary M. Horowitz, Medical College of Wisconsin, Milwaukee, WI; and Charles Linker, University of California at San Francisco, San Francisco, CA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.62.7273DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4658453PMC
December 2015

Lenalidomide and vorinostat maintenance after autologous transplant in multiple myeloma.

Br J Haematol 2015 Oct 8;171(1):74-83. Epub 2015 Jun 8.

Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.13527DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4600596PMC
October 2015

Improved accuracy of acute graft-versus-host disease staging among multiple centers.

Best Pract Res Clin Haematol 2014 Sep-Dec;27(3-4):283-7. Epub 2014 Oct 15.

Translational Research Center, The Tisch Cancer Institute, The Icahn School of Medicine at Mount Sinai Hospital, 1470 Madison Avenue, New York, NY 10029, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.beha.2014.10.011DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4381784PMC
July 2015

Graft-versus-host disease-associated angiomatosis: a clinicopathologically distinct entity.

J Am Acad Dermatol 2014 Oct 1;71(4):745-53. Epub 2014 Jul 1.

Dermatology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jaad.2014.05.034DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4165782PMC
October 2014

Hematopoietic stem-cell transplantation for advanced systemic mastocytosis.

J Clin Oncol 2014 Oct 25;32(29):3264-74. Epub 2014 Aug 25.

Celalettin Ustun, Ryan Shanley, Gregory Vercellotti, and Daniel Weisdorf, University of Minnesota, Minneapolis; William J. Hogan, Mayo Clinic, Rochester, MN; Andreas Reiter and Sebastian Kreil, Universitätsmedizin Mannheim, Mannheim; Herrad Baurmann, Stiftung Deutsche Klinik für Diagnostik, Wiesbaden; Bernd Gruhn, Jena University Hospital, Jena; Tanja Gromke, University of Essen, Essen; Eva Maria Wagner, Universitätsmedizin Mainz, Mainz; Martin Bornhäuser, Universitätsklinikum Dresden, Dresden; Christoph Schmid, Klinikum Augsburg, Ausburg, Germany; Bart L. Scott and H. Joachim Deeg, University of Washington, Seattle, WA; Ryotaro Nakamura, City of Hope National Medical Center, Duarte; Vinod Pullarkat, University of Southern California, Los Angeles, CA; Gandhi Damaj, Université de Caen, Faculté de Médecine, Caen; Faezeh Legrand, Nice University Hospital, Nice, and Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC); Ibrahim Yakoub-agha, Centre Hospitalier Régionale Universitaire, Lille; Olivier Hermine, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Necker Enfants-Malades, Université Paris 5 Faculté de Médecine et AP-HP Necker-Enfants Malades, and Centre de Référence des Mastocytoses, Paris, France; Miguel-Angel Perales and Esperanza B. Papadopoulos, Memorial Sloan-Kettering Cancer Center; Tsiporah Shore, New York-Presbyterian Hospital/Weill Cornell Medical Center, New York, NY; Robert Stuart, Medical University of South Carolina, Charleston, SC; Michael Doubek, Masaryk University, Brno, Czech Republic; Jack W. Hsu, University of Florida, Gainesville, FL; Eleni Tholouli, Manchester Royal Infirmary, Manchester, United Kingdom; Lucy A. Godley, University of Chicago, Chicago, IL; Livio Pagano, Università Cattolica del Sacro Cuore, Milan; Maria Teresa Van Lint, Istituto Di Ricovero e Cura a Carattere Scientifico San Martino-IST, Genova, Italy; Andrew Gilman, Levine Children's Hospital, Charlotte, NC; Tor Shwayder, Henry F

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.55.2018DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4876356PMC
October 2014

Genetic modification of T cells redirected toward CS1 enhances eradication of myeloma cells.

Clin Cancer Res 2014 Aug 27;20(15):3989-4000. Epub 2014 Mar 27.

Division of Hematology, Department of Internal Medicine, College of Medicine, The Ohio State University, Columbus, Ohio 43210, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-13-2510DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4119545PMC
August 2014

Improved survival after transplantation of more donor plasmacytoid dendritic or naïve T cells from unrelated-donor marrow grafts: results from BMTCTN 0201.

J Clin Oncol 2014 Aug 30;32(22):2365-72. Epub 2014 Jun 30.

Edmund K. Waller and Wayne A.C. Harris, Emory University, Atlanta, GA; Brent R. Logan, Medical College of Wisconsin, Milwaukee, WI; Steven M. Devine, Ohio State University, Columbus, OH; David L. Porter, University of Pennsylvania, Philadelphia, PA; Shin Mineishi, University of Alabama at Birmingham, Birmingham, AL; John M. McCarty, Medical College of Virginia, Richmond, VA; Corina E. Gonzalez, Georgetown University Hospital, Washington, DC; Thomas R. Spitzer, Massachusetts General Hospital, Boston, MA; Oleg I. Krijanovski, Sutter East Bay Medical Foundation, Berkeley, CA; Michael L. Linenberger and Ann Woolfrey, Fred Hutchinson Cancer Research Center, Seattle, WA; Alan Howard and Dennis L. Confer, National Marrow Donor Program, Minneapolis, MN; Juan Wu, EMMES Corporation, Rockville, MD; and Claudio Anasetti, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2013.54.4577DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4180368PMC
August 2014

FLT3L and plerixafor combination increases hematopoietic stem cell mobilization and leads to improved transplantation outcome.

Biol Blood Marrow Transplant 2014 Mar 21;20(3):309-13. Epub 2013 Dec 21.

Division of Hematology, Department of Internal Medicine, College of Medicine, Ohio State University, Columbus, Ohio; The Ohio State University Comprehensive Cancer Center, Columbus, Ohio; Blood and Marrow Transplantation Program, The James Cancer Hospital, Ohio State University, Columbus, Ohio. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2013.11.024DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3943635PMC
March 2014

Graft-versus-host disease: why have we not made more progress?

Curr Opin Hematol 2014 Mar;21(2):141-7

Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, Ohio, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MOH.0000000000000026DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4131840PMC
March 2014

Reprint of: Re-examining the role of high-dose chemotherapy in the treatment of light chain amyloidosis.

Authors:
Steven M Devine

Biol Blood Marrow Transplant 2014 Feb 12;20(2 Suppl):S2-S7. Epub 2014 Jan 12.

Blood and Marrow Transplant Program, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S10838791140001
Publisher Site
http://dx.doi.org/10.1016/j.bbmt.2013.11.035DOI Listing
February 2014

Re-examining the role of high-dose chemotherapy in the treatment of light chain amyloidosis.

Authors:
Steven M Devine

Biol Blood Marrow Transplant 2014 Jan 27;20(1):14-9. Epub 2013 Nov 27.

Blood and Marrow Transplant Program, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S10838791130055
Publisher Site
http://dx.doi.org/10.1016/j.bbmt.2013.11.015DOI Listing
January 2014

Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial.

J Clin Oncol 2013 Nov 14;31(33):4199-206. Epub 2013 Oct 14.

Philippe Armand and Edie Weller, Dana-Farber Cancer Institute; David E. Avigan, Beth Israel Deaconess Medical Center; Yi-Bin Chen, Massachusetts General Hospital, Boston, MA; Arnon Nagler, Chaim Sheba Medical Center, Tel-Hashomer; Reuven Or, Hadassah Medical Center, Jerusalem; Rinat Rotem-Yehudar, CureTech, Yavne, Israel; Steven M. Devine, The Ohio State University Comprehensive Cancer Center, Ohio State University, Columbus; Hillard M. Lazarus, Case Western Reserve University and University Hospitals Case Medical Center, Cleveland, OH; Mark S. Kaminski, University of Michigan, Ann Arbor, MI; H. Kent Holland, Northside Hospital; Edmund K. Waller, Winship Cancer Institute, Emory University, Atlanta, GA; Jane N. Winter and Leo I. Gordon, Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine; Stephanie A. Gregory, Rush Medical Center, Chicago, IL; James R. Mason, Scripps Clinic; Edward D. Ball, Moores University of California at San Diego Cancer Center, University of California, San Diego; John M. Timmerman and David Andorsky, University of California, Los Angeles, Los Angeles, CA; Joseph W. Fay, Baylor Research Institute, Baylor University Medical Center, Dallas; Chitra M. Hosing, The University of Texas MD Anderson Cancer Center, Houston, TX; David A. Rizzieri, Duke Cancer Center, Durham, NC; Joseph P. Uberti, Karmanos Cancer Institute, Detroit, MI; Markus Y. Mapara, University of Pittsburgh School of Medicine and Cancer Institute, Pittsburgh, PA.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2012.48.3685
Publisher Site
http://dx.doi.org/10.1200/JCO.2012.48.3685DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4878008PMC
November 2013

Chronic Myelogenous Leukemia, Version 1.2014.

J Natl Compr Canc Netw 2013 Nov;11(11):1327-40

From 1The University of Texas MD Anderson Cancer Center; 2Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance; 3Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine; 4Fred & Pamela Buffett Cancer Center at The Nebraska Medical Center; 5Robert H. Lurie Comprehensive Cancer Center of Northwestern University; 6Memorial Sloan-Kettering Cancer Center; 7Dana-Farber/Brigham & Women's Cancer Center; 8Huntsman Cancer Institute at the University of Utah; 9The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute; 10Massachusetts General Hospital Cancer Center; 11Stanford Cancer Institute; 12Vanderbilt-Ingram Cancer Center; 13Fox Chase Cancer Center; 14Duke Cancer Institute; 15St. Jude Children's Research Hospital/The University of Tennessee Health Science Center; 16Moffitt Cancer Center; 17University of Alabama at Birmingham Comprehensive Cancer Center; 18UCSF Helen Diller Family Comprehensive Cancer Center; 19The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; 20City of Hope Comprehensive Cancer Center; 21Roswell Park Cancer Institute; and 22National Comprehensive Cancer Network.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4234105PMC
http://dx.doi.org/10.6004/jnccn.2013.0157DOI Listing
November 2013